Acquiring Company
Flerie AB
Acquired Company
Biosergen AB
SwedenSwedenBiotechnologyFinancial ServicesHealth CareFinanceVenture CapitalAngel InvestmentMedicalBiotechnologyHealth CareDescription
Flerie AB has completed its merger with Biosergen AB, with 2,667,234 new ordinary shares issued as merger consideration. Following the issuance, Flerie has 89,364,936 ordinary shares and votes outstanding as of 30 October 2026. The announcement is a change in total shares and votes required under the Financial Instruments Trading Act.
Who to call at Flerie AB, and when
When Flerie AB changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Flerie AB raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Flerie AB, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Flerie AB. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Flerie AB makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Biosergen AB?
Biosergen AB was acquired by Flerie AB, based in Sweden. The deal was reported on October 30, 2026. Flerie AB focuses on developing innovative treatments targeting various medical conditions. The company is engaged in advancing healthcare solutions through strategic mergers. Flerie AB is privately held and operates in Biotechnology.
When did Flerie AB acquire Biosergen AB?
Flerie AB's acquisition of Biosergen AB was reported on October 30, 2026. Flerie AB has completed its merger with Biosergen AB, with 2,667,234 new ordinary shares issued as merger consideration. Following the issuance, Flerie has 89,364,936 ordinary shares and votes outstanding as of 30 October 2026. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Biosergen AB do?
Biosergen AB is a biotechnology company that develops innovative drug candidates for treating serious infections, particularly invasive fungal infections. The company is engaged in exploring various strategic options to optimize its assets. It is privately held, operating in Biotechnology, and is based in Sweden.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.